- Home
- CRGY vs EWTX Comparison
CRGY vs EWTX Comparison
Compare CRGY & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRGY | EWTX |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRGY | EWTX |
|---|---|---|
| Price | $12.74 | $32.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $14.36 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 8.3M | 739.7K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,579,782,000.00 | N/A |
| Revenue This Year | $29.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $99.08 | ★ N/A |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $7.68 | $11.50 |
| 52 Week High | $14.02 | $34.00 |
Technical Indicators
Market Signals| Indicator | CRGY | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 58.59 |
| Support Level | $8.29 | $28.72 |
| Resistance Level | $14.02 | N/A |
| Average True Range (ATR) | 0.57 | 1.48 |
| MACD | -0.15 | 0.15 |
| Stochastic Oscillator | 41.80 | 76.47 |
Price Performance
Historical ComparisonAbout CRGY Crescent Energy Company
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.